CUE Message Board Post 10046176 | Cue Biopharma Inc.
home / stock / cue / cue message board
mahavirmete
(investorshub)
Posted on: Apr/06/2022 01:32:33
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168457956
CUE Insider Buy
News, Short Squeeze, Breakout and More Instantly...
-
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company anticipates annualized capital and workforce requirements to be reduced by approximately 25...
-
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA ® (pembrolizumab) Median overall survival (mOS) of 20.8 months in second...
-
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it will participate in two investor confe...